Treatment

The Prep-02/JSAP05 trial, a phase II/III study, evaluated preoperative chemotherapy versus surgery-first in patients with resectable pancreatic ductal adenocarcinoma. A total of 364 patients were enrolled: one group received two cycles of gemcitabine plus S-1 before surgery, while the other underwent immediate surgery. Both groups were advised to complete six months of postoperative S-1. Results […]

Top-line results from the Phase 3 HERIZON-GEA-01 trial show that zanidatamab-based treatment combinations significantly improve outcomes for people with previously untreated HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma. The study compared zanidatamab plus chemotherapy and zanidatamab plus tislelizumab plus chemotherapy with the current standard treatment of trastuzumab plus chemotherapy. Both zanidatamab regimens led to meaningful

A new recommendation supports approving the combination of tafasitamab, lenalidomide, and rituximab for adults with relapsed or refractory follicular lymphoma who have already received at least one systemic therapy. This recommendation is based on results from the phase 3 inMIND trial, which directly compared the tafasitamab triplet with the commonly used lenalidomide plus rituximab doublet.

Organometallic complexes—cancer-fighting compounds built around metal-carbon bonds—are emerging as a more selective alternative to traditional platinum drugs like cisplatin. While platinum treatments remain effective, they often damage healthy cells and quickly lead to resistance. New metal-based designs aim to target cancer more precisely and avoid these limitations. Cyclometalated complexes are especially promising because their chemistry

NaPi2b, a sodium-dependent phosphate transporter, is emerging as a promising target for platinum-resistant ovarian cancer, a setting with few effective treatments. Highly expressed in high-grade serous ovarian, fallopian tube, and peritoneal cancers—but low in normal tissue—NaPi2b is ideal for selective delivery via antibody-drug conjugates (ADCs). Earlier NaPi2b-targeted ADCs, like lifastuzumab vedotin and upifitamab rilsodotin, showed

A new study suggests that GLP-1 receptor agonists—including Ozempic, Wegovy, and Mounjaro—may improve survival in patients with colon cancer. These drugs, commonly used for type 2 diabetes and weight loss, were linked to a five-year mortality rate of 15.5%, compared with 37.1% in patients not taking them, meaning users were less than half as likely

DB-1305/BNT325 is an investigational antibody-drug conjugate (ADC) designed to target TROP-2, a protein commonly found on triple-negative breast cancer (TNBC) cells. Once attached, it delivers a topoisomerase-1 inhibitor to help kill the cancer. Each antibody carries about four drug molecules. This treatment is being tested in a Phase 1/2 study in patients with metastatic TNBC

The Phase 3 PEAK trial showed that adding the targeted drug bezuclastinib to sunitinib significantly improved outcomes for people with advanced gastrointestinal stromal tumors (GIST) who could not take imatinib or whose cancer had progressed on it. The combination cut the risk of cancer progression or death by half compared with sunitinib alone. Patients receiving

A Phase 3 trial, STELLAR-303, shows that combining zanzalintinib (XL092) with atezolizumab (Tecentriq) extends survival in patients with metastatic colorectal cancer compared with standard treatment regorafenib (Stivarga). Patients previously treated with chemotherapy and who were not MSI-high lived 10.9 months on the combination versus 9.4 months on regorafenib, with slower disease progression (3.7 vs. 2.0 months) and higher disease

Glioblastoma multiforme (GBM) is the most aggressive adult brain cancer, and treatment remains challenging. Standard therapy combines surgery, radiation, and temozolomide (TMZ) chemotherapy, sometimes with tumor-treating fields. A key factor is MGMT promoter methylation—tumors with methylation respond better to TMZ, improving survival from about 12 to nearly 15 months. Genetic profiling, including TERT promoter mutations, EGFR